Astrana Health (ASTH) Q1 2026 earnings review
Massive Top-Line Growth Tempered by Margin Compression and Accounting Red Flags
Astrana Health delivered a powerful revenue beat in Q1 2026, driven by the ongoing integration of Prospect Health and an aggressive shift toward full-risk contracts. Total revenue surged 56% YoY to $965.1M, and Free Cash Flow exploded 372% to $64.1M. However, beneath the impressive headline growth lies a Reversing margin narrative in its core Care Partners segment—revenue jumped 51%, but operating income actually fell 11%. Compounding the operational mixed bag is a disclosed material weakness in internal controls over financial reporting related to acquisition accounting, which casts a shadow over an otherwise stellar growth story.
🐂 Bull Case
The Care Enablement platform is actively absorbing acquired entities and automating workflows. G&A expenses dropped 70 bps YoY to 6.4% of revenue, demonstrating that Astrana's technology infrastructure can scale profitably.
Full-risk arrangements now account for 80% of Care Partners capitation revenue (up from 65% in 2024). This structural shift drastically increases revenue capture and aligns incentives for long-term margin expansion.
🐻 Bear Case
Management admitted to a material weakness in internal controls regarding purchase accounting, forcing a 10-K delay. For a company growing heavily via M&A (Prospect, CHS), acquisition accounting failures are a massive red flag.
Care Partners operating income declined 11% YoY despite 51% revenue growth. The cost of taking on new full-risk cohorts and integrating higher-trend Prospect patients is currently dragging down unit economics.
⚖️ Verdict: ⚪
Neutral. The sheer scale and cash generation are undeniable, but the combination of a material accounting weakness and severe negative operating leverage in the largest business segment demands investor caution.
Key Themes
Shift to Full-Risk Drives Top-Line Explosion
Astrana's deliberate, multi-year strategy to transition to full-risk accountable care contracts is Accelerating. Full-risk now comprises 80% of capitation revenue, a sharp increase from 76% at year-end 2025 and 65% in 2024. This structural shift is the primary engine behind the 51% revenue growth in the Care Partners segment.
Care Partners Operating Margin Collapse
A massive contradiction to the bullish narrative emerged in the Care Partners segment. Despite generating $909.7M in revenue (+51% YoY), operating income actually contracted 11% YoY to $39.5M. The segment's operating margin plummeted from ~7.4% in 25Q1 to 4.3% in 26Q1. This Reversing trend indicates significant friction in absorbing the higher medical cost trend of the Prospect acquisition and the upfront costs of onboarding new full-risk members.
Care Enablement Segment Becomes a Profit Engine
While Care Partners struggled with margins, the Care Enablement (technology) segment is Accelerating wildly. Revenue grew 122% YoY to $87.7M, and operating income skyrocketed 470% to $20.2M. This confirms that Astrana is successfully monetizing its proprietary platform across its expanding provider network.
Material Weakness in Acquisition Accounting
Management disclosed a material weakness in internal controls over financial reporting, specifically related to acquisition and purchase accounting. Consequently, the company had to file a Form 12b-25. While the CFO claimed this caused no financial restatement, for a business reliant on rolling up large physician groups, a broken M&A accounting process is a critical governance concern.
AI and Workflow Automation Generating Leverage
Astrana is deploying proprietary AI tools to automate prior authorizations, claims processing, and clinical workflow orchestration. This specific technological innovation directly reduced General & Administrative expenses to 6.4% of revenue in 26Q1, down 70 bps from 7.1% a year ago, proving the model can achieve enterprise-level scale efficiencies.
Macro: Medicaid and Exchange Disenrollment
Macro regulatory pressures continue to loom. Guidance assumes a severe 10% to 15% disenrollment in Medicaid and low double-digit declines in Exchange memberships. Coupled with a projected 1-1.5% negative spread on Medicaid rate vs. acuity, this creates a structural headwind that will require flawless execution in the Medicare Advantage book to offset.
Prospect Integration Yielding Results
The integration of Prospect Health remains on track. PCP retention remains high at over 97%, and management expects to hit the high end of their $12M-$15M annualized synergy target. The successful ingestion of this asset is the linchpin of the company's 2026 financial roadmap.
Other KPIs
Accelerating dramatically. FCF surged 372% YoY from $13.6M in 25Q1. This exceptional conversion of EBITDA to cash allowed the company to deleverage ahead of schedule to 2.2x net leverage and supports the recently doubled $100M share repurchase authorization.
Revenue surged 155% YoY, but the segment generated an operating loss of $3.0M (a 5% deterioration YoY). While the top line is expanding aggressively as Astrana builds out its employed provider network, this unit remains a loss leader heavily reliant on the enablement and capitation arms for enterprise profitability.
Guidance
Stable. The $982.5M midpoint implies a 50% YoY increase (benefiting from M&A base effects) but represents a marginal 1.8% sequential growth from Q1 2026, indicating organic growth is normalizing after the Prospect-driven step-up.
Stable. The $67.5M midpoint implies roughly 40% YoY growth from Q2 2025's $48.1M, but essentially flat sequential growth compared to Q1 2026's $66.3M.
Decelerating. The midpoint of $3.95B implies 24% YoY growth compared to the massive 56% growth achieved in FY 2025. Management heavily caveated this with assumed headwinds from Medicaid/Exchange disenrollment.
Accelerating. The $265M midpoint implies a 29% YoY growth from FY 2025's $205.4M. This outpaces the projected top-line growth (24%), signaling management's confidence in extracting Prospect synergies and Care Enablement leverage in the back half of the year.
Key Questions
Care Partners Margin Economics
Care Partners operating income fell 11% despite a 51% revenue jump. Is this structural degradation due to taking on higher-acuity populations, or purely transient onboarding costs for new full-risk cohorts? When does this margin inflection reverse?
Internal Controls Remediation
With the 10-K delayed due to material weaknesses in acquisition accounting, what specific structural and personnel changes are being made to ensure upcoming roll-ups don't trigger further financial reporting failures?
Medicaid Rate/Acuity Mismatch
Guidance bakes in a negative 1-1.5% spread on Medicaid. How are negotiations progressing with state payers to rectify this, and what is the timeline for potential relief?
Care Delivery Segment Viability
The Care Delivery segment continues to post operating losses despite massive revenue growth (+155%). What is the long-term timeline for this segment to achieve standalone profitability?